Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.39 |
| ▸ | PIM1 | P11309 | 4/20 | 0.39 |
| ▸ | FEN1 | P39748 | 4/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379868 | 0.85 | NPC1 (0.42) | NPC1F2F10F7F3 | |
| SCHEMBL3391889 | 0.83 | GABRG2 (0.42) | NPC1F2F10F7F3 | |
| SCHEMBL247583 | 0.83 | NPC1 (0.44) | NPC1F2F10F7F3 | |
| SCHEMBL3393479 | 0.81 | IKBKE (0.50) | NPC1F2F10F7F3 | |
| SCHEMBL247776 | 0.80 | NPC1 (0.40) | NPC1F2F10F7F3 | |
| SCHEMBL3385405 | 0.80 | NPC1 (0.41) | NPC1F2F10F7F3 | |
| SCHEMBL246201 | 0.80 | TBK1 (0.49) | NPC1F2F10F7F3 | |
| SCHEMBL250767 | 0.79 | NPC1 (0.43) | NPC1F2F10F7F3 | |
| SCHEMBL3382315 | 0.78 | NPC1 (0.40) | NPC1F2F10F7F3 | |
| SCHEMBL246233 | 0.78 | NPC1 (0.41) | NPC1F2F10F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2585461-A1 | 2,4- DIARYL - SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | Merck Patent GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | NPC1 2454/4885F2 4443/4885F10 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.